Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Description:
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).
Sponsor:
Fusion Pharmaceuticals, Inc.Contacts:
Clinical Trials Fusion Pharmaceuticals Clinical Operationsclinicaltrials@fusionpharma.com
1 (888) 506-4215
Government Study Link:
NCT06147037 - Click here to see study onClinicalTrials.gov
- Adequate organ function
- Histologically/cytologically confirmed solid tumor, metastatic, locally advanced recurrent or inoperable
- Measurable diseases as defined by RECIST v1.1
- Progressed disease despite treatment, standard therapy not available contradicted not tolerable or no standard therapy
- ECOG performance status 0 or 1
- Prior anti-cancer therapy unless adequate washout and recovery from toxicities
- Previous treatment with any systemic radiopharmaceutical
- Uncontrolled pleural effusion, pericardial effusion, ascites requiring drainage
- Contraindications to or inability perform the imaging procedures required in study
- Radiation therapy within 28 days prior to the first dose of Indium
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
Stanford, California 94305, United States
St. Louis, Missouri, United States
Principal Investigator
Richard Wahl, MD
Chicago, Illinois 60637, United States
Principal Investigator
Aditya Juloori, MD
Seattle, Washington 98109, United States
Principal Investigator
Delphine Chen, MD
Houston, Texas 77030, United States
Principal Investigator
Jordi Rodon Ahnert, MD
Boston, Massachusetts 02215, United States
Principal Investigator
Heather Jacene, MD
Pittsburgh, Pennsylvania 15213, United States
Afghanistan 🇦🇫
Principal Investigator
Éric Turcotte, MD
Canada 🇨🇦
H2X 3E4, Montréal, Quebec, Canada
Principal Investigator
Daniel Juneau, MD
